General Population Survey 2018/19. Prevalence and patterns of drug use among the general population, measured by probabilistic surveys of the adult and school population, is one of five EMCDDA key indicators that assess the drugs situation and allow monitoring of progress towards EU and Member State drug policy targets. The aim of this key indicator is to provide valid, reliable and comparable information on the extent, the distribution and the patterns of drug use in the general population (adults and young people), the characteristics of drug users and their perceptions. Each Member State is required to complete a regular survey to estimate national drug use prevalence and Ireland has conducted four of these general population surveys (2002/03, 2006/07, 20010/11 and 2014/15).
Deadline
The time limit for receipt of tenders was 2018-06-25.
The procurement was published on 2018-05-18.
Suppliers
The following suppliers are mentioned in award decisions or other procurement documents:
Contract notice (2018-05-18) Object Scope of the procurement
Title: Survey conduction services
Reference number: HRB 2018 - Gen Pop Survey
Short description:
General Population Survey 2018/19.
Prevalence and patterns of drug use among the general population, measured by probabilistic surveys of the adult and school population, is one of five EMCDDA key indicators that assess the drugs situation and allow monitoring of progress towards EU and Member State drug policy targets. The aim of this key indicator is to provide valid, reliable and comparable information on the extent, the distribution and the patterns of drug use in the general population (adults and young people), the characteristics of drug users and their perceptions. Each Member State is required to complete a regular survey to estimate national drug use prevalence and Ireland has conducted four of these general population surveys (2002/03, 2006/07, 20010/11 and 2014/15).
Prevalence and patterns of drug use among the general population, measured by probabilistic surveys of the adult and school population, is one of five EMCDDA key indicators that assess the drugs situation and allow monitoring of progress towards EU and Member State drug policy targets. The aim of this key indicator is to provide valid, reliable and comparable information on the extent, the distribution and the patterns of drug use in the general population (adults and young people), the characteristics of drug users and their perceptions. Each Member State is required to complete a regular survey to estimate national drug use prevalence and Ireland has conducted four of these general population surveys (2002/03, 2006/07, 20010/11 and 2014/15).
Notice metadata
Original language: English ๐ฃ๏ธ
Document type: Contract notice
Nature of contract: Services
Regulation: European Union
Common procurement vocabulary (CPV)
Code: Survey conduction services๐ฆ
Additional CPV: Survey services๐ฆ Place of performance
NUTS region: รire/Ireland
๐๏ธ
Procedure
Procedure type: Open procedure
Type of bid: Submission for all lots
Award criteria
The most economic tender
Object Scope of the procurement
Short description:
General Population Survey 2018/19.
Prevalence and patterns of drug use among the general population, measured by probabilistic surveys of the adult and school population, is one of five EMCDDA key indicators that assess the drugs situation and allow monitoring of progress towards EU and Member State drug policy targets. The aim of this key indicator is to provide valid, reliable and comparable information on the extent, the distribution and the patterns of drug use in the general population (adults and young people), the characteristics of drug users and their perceptions. Each Member State is required to complete a regular survey to estimate national drug use prevalence and Ireland has conducted four of these general population surveys (2002/03, 2006/07, 20010/11 and 2014/15).
Prevalence and patterns of drug use among the general population, measured by probabilistic surveys of the adult and school population, is one of five EMCDDA key indicators that assess the drugs situation and allow monitoring of progress towards EU and Member State drug policy targets. The aim of this key indicator is to provide valid, reliable and comparable information on the extent, the distribution and the patterns of drug use in the general population (adults and young people), the characteristics of drug users and their perceptions. Each Member State is required to complete a regular survey to estimate national drug use prevalence and Ireland has conducted four of these general population surveys (2002/03, 2006/07, 20010/11 and 2014/15).
Estimated total value: 575 000 EUR ๐ฐ
Short description:
The Health Research Board (HRB) is the lead agency in Ireland supporting and funding health research. We provide funding, maintain health information systems and conduct research linked to national health priorities. Our aim is to improve people's health, build health research capacity and make a significant contribution to Ireland's knowledge economy. Our latest Corporate Strategy clearly outlines how we hope to achieve this working in partnership with other organizations.
The Health Research Board (HRB) is the lead agency in Ireland supporting and funding health research. We provide funding, maintain health information systems and conduct research linked to national health priorities. Our aim is to improve people's health, build health research capacity and make a significant contribution to Ireland's knowledge economy. Our latest Corporate Strategy clearly outlines how we hope to achieve this working in partnership with other organizations.
Prevalence and patterns of drug use among the general population, measured by probabilistic surveys of the adult and school population, is one of five EMCDDA key indicators that assess the drugs situation and allow monitoring of progress towards EU and Member State drug policy targets. The aim of this key indicator is to provide valid, reliable and comparable information on the extent, the distribution and the patterns of drug use in the general population (adults and young people), the characteristics of drug users and their perceptions. Each Member State is required to complete a regular survey to estimate national drug use prevalence and Ireland has conducted four of these general population surveys (2002/03, 2006/07, 20010/11 and 2014/15).1 Previous surveys were conducted simultaneously in Ireland and Northern Ireland (on behalf of the Public Health Information and Research Branch (PHIRB), within the Department of Health, Social Services and Public Safety). The 2018/19 survey will be conducted in Ireland only.
Prevalence and patterns of drug use among the general population, measured by probabilistic surveys of the adult and school population, is one of five EMCDDA key indicators that assess the drugs situation and allow monitoring of progress towards EU and Member State drug policy targets. The aim of this key indicator is to provide valid, reliable and comparable information on the extent, the distribution and the patterns of drug use in the general population (adults and young people), the characteristics of drug users and their perceptions. Each Member State is required to complete a regular survey to estimate national drug use prevalence and Ireland has conducted four of these general population surveys (2002/03, 2006/07, 20010/11 and 2014/15).1 Previous surveys were conducted simultaneously in Ireland and Northern Ireland (on behalf of the Public Health Information and Research Branch (PHIRB), within the Department of Health, Social Services and Public Safety). The 2018/19 survey will be conducted in Ireland only.
1) Survey brief
The Health Research Board will commission a fifth survey, to be completed between September 2018 and April 2019. The survey will require a nationally representative proability sample of the persons aged 15 years and over and resident in households in Ireland. The sample size will be in the order of 8,302. The survey will use a pre-prepared questionnaire and interviews will be conducted face-to-face in respondentsโ homes using CAPI.
The Health Research Board will commission a fifth survey, to be completed between September 2018 and April 2019. The survey will require a nationally representative proability sample of the persons aged 15 years and over and resident in households in Ireland. The sample size will be in the order of 8,302. The survey will use a pre-prepared questionnaire and interviews will be conducted face-to-face in respondentsโ homes using CAPI.
Estimated value excluding VAT: 575 000 EUR ๐ฐ
Procedure
Time of receipt of tenders: 12:00
Languages in which tenders or requests to participate may be submitted: English ๐ฃ๏ธ
Tender validity period: 12 months
Tender opening date: 2018-06-25 ๐
Tender opening time: 12:00
Complementary information Review body
Name: High Court
Postal address: Chief Registrar, The Four Courts
Postal town: Dublin
Postal code: 7
Country: Ireland ๐ฎ๐ช
Phone: +353 18886000๐
E-mail: highcourtcentraloffice@courts.ie๐ง
Source: OJS 2018/S 096-219063 (2018-05-18)
Contract award notice (2018-11-22) Object Scope of the procurement
Short description:
General Population Survey 2018/19.
Prevalence and patterns of drug use among the general population, measured by probabilistic surveys of the adult and school population, is 1 of 5 EMCDDA key indicators that assess the drugs situation and allow monitoring of progress towards EU and Member State drug policy targets. The aim of this key indicator is to provide valid, reliable and comparable information on the extent, the distribution and the patterns of drug use in the general population (adults and young people), the characteristics of drug users and their perceptions. Each Member State is required to complete a regular survey to estimate national drug use prevalence and Ireland has conducted four of these general population surveys (2002/03, 2006/07, 20010/11 and 2014/15).
Prevalence and patterns of drug use among the general population, measured by probabilistic surveys of the adult and school population, is 1 of 5 EMCDDA key indicators that assess the drugs situation and allow monitoring of progress towards EU and Member State drug policy targets. The aim of this key indicator is to provide valid, reliable and comparable information on the extent, the distribution and the patterns of drug use in the general population (adults and young people), the characteristics of drug users and their perceptions. Each Member State is required to complete a regular survey to estimate national drug use prevalence and Ireland has conducted four of these general population surveys (2002/03, 2006/07, 20010/11 and 2014/15).
Total value of the procurement: 574 675 EUR ๐ฐ
Notice metadata
Document type: Contract award notice
Object Scope of the procurement
Short description:
Prevalence and patterns of drug use among the general population, measured by probabilistic surveys of the adult and school population, is 1 of 5 EMCDDA key indicators that assess the drugs situation and allow monitoring of progress towards EU and Member State drug policy targets. The aim of this key indicator is to provide valid, reliable and comparable information on the extent, the distribution and the patterns of drug use in the general population (adults and young people), the characteristics of drug users and their perceptions. Each Member State is required to complete a regular survey to estimate national drug use prevalence and Ireland has conducted four of these general population surveys (2002/03, 2006/07, 20010/11 andโฆ
โฆ 2014/15).
โฆ 2014/15). 1 Previous surveys were conducted simultaneously in Ireland and Northern Ireland (on behalf of the Public Health Information and Research Branch (PHIRB), within the Department of Health, Social Services and Public Safety). The 2018/19 survey will be conducted in Ireland only.
1) Survey brief:
The Health Research Board will commission a fifth survey, to be completed between September 2018 and April 2019. The survey will require a nationally representative proability sample of the persons aged 15 years and over and resident in households in Ireland. The sample size will be in the order of 8 302. The survey will use a pre-prepared questionnaire and interviews will be conducted face-to-face in respondentsโ homes using CAPI.
The Health Research Board will commission a fifth survey, to be completed between September 2018 and April 2019. The survey will require a nationally representative proability sample of the persons aged 15 years and over and resident in households in Ireland. The sample size will be in the order of 8 302. The survey will use a pre-prepared questionnaire and interviews will be conducted face-to-face in respondentsโ homes using CAPI.
Procedure Award criteria
Quality criterion (name): Experience in managing large population surveys
Quality criterion (weighting): 35 %
Quality criterion (name): Qualifications of staff assigned to this project
Quality criterion (weighting): 10 %
Quality criterion (name): Ability to deliver key outputs to a tight deadline
Understanding of the requirements of the contract and feasibility of the proposed plan
Clarity in outlining the proposed plan, including details around milestones and data analysis
Quality criterion (weighting): 10
Price (weighting): 25 %
Award of contract
Date of contract conclusion: 2018-09-28 ๐
Name: Ipsos MRBI / MRBI Market Research Ltd
National registration number: 9701145N
Postal address: Block 3 Blackrock Business Park
Postal town: Co Dublin
Postal code: Carysfort Avenue, Bl
Country: Ireland ๐ฎ๐ช
Phone: +353 14389048๐
E-mail: kieran.oleary@ipsos.com๐ง
Internet address: http://www.ipsosmrbi.com๐
Total value of the procurement: 574 675 EUR ๐ฐ
Information about tenders
Number of tenders received: 4
Source: OJS 2018/S 228-522055 (2018-11-22)